Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
UBS
Daiichi Sankyo
Julphar
Accenture
US Department of Justice
Argus Health
McKinsey
Dow

Generated: January 21, 2019

DrugPatentWatch Database Preview

Lanthanum carbonate - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for lanthanum carbonate and what is the scope of lanthanum carbonate freedom to operate?

Lanthanum carbonate is the generic ingredient in two branded drugs marketed by Shire Dev Llc, Shire Llc, and Natco Pharma Ltd, and is included in three NDAs. There are five patents protecting this compound and two Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Lanthanum carbonate has one hundred and twenty-one patent family members in thirty-five countries.

There are nine drug master file entries for lanthanum carbonate. Three suppliers are listed for this compound.

Pharmacology for lanthanum carbonate
Synonyms for lanthanum carbonate
0M78EU4V9H
587-26-8
AC1L52T0
ACMC-1BB7U
C3La2O9
Carbonic acid, lanthanum(3+) salt (3:2)
Carbonic acid,lanthanum(3+) salt (3:2)
CTK5A8757
D0H1LO
DB06792
Dilanthanum tricarbonate
EINECS 209-599-5
Fosrenol
Foznol
HSDB 7758
IN002128
IN016806
Lanthanum (III) carbonate
lanthanum carbonate (2:3)
Lanthanum carbonate anhydrous
Lanthanum sesquicarbonate
Lanthanum(3 ) carbonate
Lanthanum(3+) carbonate
lanthanum(3+) tricarbonate
LANTHANUMCARBONATE
LS-186384
NZPIUJUFIFZSPW-UHFFFAOYSA-H
Phosbloc
Phosphate binding agent, Shire/Johnson Matthey
Project Lambda, Shire/Johnson Matthey
TC-166469
UNII-0M78EU4V9H

US Patents and Regulatory Information for lanthanum carbonate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Shire Llc FOSRENOL lanthanum carbonate TABLET, CHEWABLE;ORAL 021468-003 Nov 23, 2005 AB RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Shire Llc FOSRENOL lanthanum carbonate TABLET, CHEWABLE;ORAL 021468-001 Oct 26, 2004 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Natco Pharma Ltd LANTHANUM CARBONATE lanthanum carbonate TABLET, CHEWABLE;ORAL 090978-001 Aug 11, 2017 AB RX No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Shire Llc FOSRENOL lanthanum carbonate TABLET, CHEWABLE;ORAL 021468-004 Nov 23, 2005 AB RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Shire Dev Llc FOSRENOL lanthanum carbonate POWDER;ORAL 204734-002 Sep 24, 2014 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Shire Llc FOSRENOL lanthanum carbonate TABLET, CHEWABLE;ORAL 021468-002 Oct 26, 2004 AB RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Expired US Patents for lanthanum carbonate

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Shire Llc FOSRENOL lanthanum carbonate TABLET, CHEWABLE;ORAL 021468-001 Oct 26, 2004 ➤ Try a Free Trial ➤ Try a Free Trial
Shire Dev Llc FOSRENOL lanthanum carbonate POWDER;ORAL 204734-002 Sep 24, 2014 ➤ Try a Free Trial ➤ Try a Free Trial
Shire Llc FOSRENOL lanthanum carbonate TABLET, CHEWABLE;ORAL 021468-002 Oct 26, 2004 ➤ Try a Free Trial ➤ Try a Free Trial
Shire Dev Llc FOSRENOL lanthanum carbonate POWDER;ORAL 204734-001 Sep 24, 2014 ➤ Try a Free Trial ➤ Try a Free Trial
Shire Llc FOSRENOL lanthanum carbonate TABLET, CHEWABLE;ORAL 021468-004 Nov 23, 2005 ➤ Try a Free Trial ➤ Try a Free Trial
Shire Llc FOSRENOL lanthanum carbonate TABLET, CHEWABLE;ORAL 021468-003 Nov 23, 2005 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Supplementary Protection Certificates for lanthanum carbonate

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB06/036 United Kingdom ➤ Try a Free Trial SPC/GB06/036: 20061027
2008005 Lithuania ➤ Try a Free Trial PRODCUT NAME: LANTANO KARBONATO HIDRATAS; NAT. REG. DATE/NO: LT/1/07/0776/001-021; FIRST REG. DATE: 20040319
2008005,C0817639 Lithuania ➤ Try a Free Trial PRODUCT NAME: LANTANO KARBONATO HIDRATAS; NAT. REGISTRATION NO/DATE: LT/1/07/0776/001-021 20071003; FIRST REGISTRATION: 17192, 2004-03-19 ; 18466, 2004-03-19; 21073, 2004-10-19; 21074 20041029
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Healthtrust
Cipla
AstraZeneca
QuintilesIMS
Farmers Insurance
Daiichi Sankyo
Citi
Mallinckrodt
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.